Biopharma | June 05, 2026
Suven Life reports positive interim review for phase 3 Alzheimer’s therapy
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
Independent DSMB recommends continuation of Masupirdine without modifications as enrollment reaches 88% in global trial
Exclusive partnership to expand access to high-quality seamless anodized aluminium packaging for sterile APIs and pharmaceutical products across India.
Targeting deadly drug-resistant acinetobacter infections
Highlights potential for at-home heart attack risk assessment, offering a new approach to reducing treatment delays
Following the completion of the acquisition on June 3, Noctrix’s flagship product, Nidra will become part of ResMed’s broader sleep medicine portfolio
A first-of-its-kind national platform honouring the people and institutions shaping the next chapter of life sciences in India
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
The safety profile was described as manageable, though not without notable toxicities
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
